The US FDA inspected the site between August 26 and September 3, 2025. The facility manufactures and supplies rh-Insulin and the biosimilar Pegfilgrastim drug substance to the US. rh-Insulin refers to human recombinant insulin.
The US FDA inspected the site between August 26 and September 3, 2025. The facility manufactures and supplies rh-Insulin and the biosimilar Pegfilgrastim drug substance to the US. rh-Insulin refers to human recombinant insulin.